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Fibroblast-like synoviocytes (FLSs) acquire aggressive phenotypes characterized with 
enhanced migration abilities and inherent invasive qualities in rheumatoid arthritis (RA). 
Smoothened (Smo) is a key component of sonic hedgehog (Shh) signaling and contrib-
utes to tumor cell invasion and metastasis. The objective of this study is to investigate 
the role of Smo in the modulation of cell migration and explore the underlying molecular 
mechanism(s). FLSs were isolated from RA synovium. Shh levels were regulated by a 
Smo agonist (purmorphamine), Smo antagonist (KAAD-cyclopamine), or small interfering 
RNA targeting the Smo gene (Smo-siRNA) in RA-FLSs. Expression of Smo was detected 
by real-time PCR and western blot analysis. Cell migration was examined by Transwell 
assay and activation of Rho GTPases was measured by pull-down assays. Incubation 
with purmorphamine resulted in a significant increase of cell migration and activation 
of Rho GTPase signaling compared to controls (P <  0.05). However, treatment with 
KAAD-cyclopamine or transfection with Smo-siRNA suppressed migration of RA-FLSs 
and showed an inhibitory effect of Rho GTPase signaling. Together, these results sug-
gest that Smo plays an important role in RA-FLSs migration through activation of Rho 
GTPase signaling and may contribute to progression of RA, thus, targeting Shh signal 
may have a therapeutic potential in patients with RA.
Keywords: rheumatoid arthritis, smoothened protein, sonic hedgehog signaling, migration, fibroblast-like 
synoviocyte
inTrODUcTiOn
Activated fibroblast-like synoviocytes (FLSs) comprising the major cell population of the hyperplas-
tic synovial linings have a central role in the pathogenesis of rheumatoid arthritis (RA). The FLSs of 
RA (RA-FLSs) display pathologic features including excessive proliferation, resistance to apoptosis, 
enhanced migration, and invasive properties (1). The aggressive phenotype of RA-FLSs was con-
firmed in a cartilage-severe combined immune deficient (SCID) mouse implantation model, show-
ing that RA-FLSs spontaneously adhere to and invade into the articular cartilage (2). The tumor-like 
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behavior of RA synoviocytes contributes to synovial hypertrophy 
and formation of invasive pannus tissue and ultimately leading to 
joint destruction (3). Therefore, therapies suppressing the tumor-
like behavior of RA-FLSs could be one of the potential approaches 
for the treatment of RA, which could be a complement for the 
current immune-directed therapies.
Sonic hedgehog (Shh) signaling pathway is active in embry-
onic development; however, this morphogenetic signaling 
pathway is quiescent in healthy adult tissues. Recent studies 
reported that Shh signaling could function through “canonical 
signaling” or “non-canonical signaling.” In the canonical path-
way, Shh signaling is launched by binding of Shh ligand to the 
transmembrane receptor, patched, and then the suppression 
of Smoothened (Smo) is reversed, resulting in the activation 
of Gli family of zinc-finger transcription factors and expres-
sion of downstream target genes (4). In the non-canonical 
Shh signaling pathway, Smo signals through heterotrimeric G 
proteins and stimulates the activation of Rho GTPases, and 
the signaling is independent of Gli activation (5). Smo is a 
key component in both the canonical and non-canonical Shh 
signaling pathway.
Accumulated evidence has suggested that aberrant activation 
and dysregulation of Shh signaling was also involved in adult 
tissues of various cancers, including basal cell carcinoma (BCC), 
medulloblastoma, lung, pancreatic, gastric, and renal cancers (6, 
7). It has been demonstrated that Shh either directly regulates 
cellular growth and survival or indirectly influences the tumor 
stroma (8). Furthermore, overexpression of Shh signaling con-
tributes to the invasiveness of cancer and the progression of non-
invasive cancer to invasive cancer (9, 10). The non-canonical Shh 
signaling also promotes cell migration including FLSs migration 
and endothelial cell tubulogenesis (5, 11).
Recently, we have identified the overexpression of Shh signal-
ing in RA synovium and selective inhibition of Shh by blocking 
Smo suppressed the proliferation of RA-FLSs, accompanying 
with the decreased expression of Gli1 in FLSs isolated from RA 
synovium (RA-FLSs) (12, 13). Others recently also demonstrated 
that Shh/Gli signaling contributes to proliferation of RA-FLSs 
(14). These observations suggest that Shh signaling may involve 
in the cell survival in a canonical manner. Additionally, previous 
studies also revealed that Rho GTPases including RhoA, Rac1, 
and Cdc42 contributed to abnormal migration and invasion of 
RA-FLSs (15–17). However, it is unclear whether Shh signaling 
has any effects on migration of RA-FLSs. In the current study, 
we made a new observation that stimulating and inhibiting Smo 
markedly modulates RA-FLSs migration. Moreover, we also 
demonstrated that the effect of Shh signal on RA-FLSs is mostly 
mediated by activating Rho GTPases.
MaTerials anD MeThODs
ethics and samples
Han Chinese patients, including six patients with active RA 
(n = 6, 3 males, 3 females, mean age 54.16 ± 10.60 years), eight 
control patients with OA (n = 4, 2 males, 2 females, mean age 
61.5 ±  4.6 years) and four patients with knee traumatic injury 
(n = 4, 2 males, 2 females, mean age 33.50 ± 6.60), were recruited 
from the third Affiliated Hospital at Sun Yat-sen University in 
Guangzhou, China, from January to August 2013. All the sub-
jects collected were taking DMARDs, including methotrexate 
(10–15 mg/week) in combination with leflunomide (20 mg/day) 
or sulfasalazine (1.5–2 g/day). Some patients were treated with 
biologics (infliximab or adalimumab or tocilizumab) for at least 
6 months. For patients suffering from joint pain or dysfunction, 
NSAIDs or low dose of steroid was used. Despite receiving inten-
sive therapies, the patients were still with high disease activity and 
rapid radiographic progression. Synovial tissues were obtained 
during knee arthroscopy. The arthroscopy was applied in RA 
patients with severe cartilage or bone destruction by synovial 
hyperplasia that results in joint dysfunction or disabilities. 
One of the two surgical approaches, total joint replacement, or 
synovectomy was applied with the patients’ consents (18). RA 
patients were classified according to the 1987 American College 
of Rheumatology (ACR) revised classification criteria (19) and 
exhibited moderate to severe disease activity (disease activity 
score of 28 joint counts >3.2). This study was approved by the 
Medical Ethics Committee of the third Affiliated Hospital of Sun 
Yat-sen University. Written informed consent was obtained from 
all patients.
cell culture and stimulation
Fibroblast-like synoviocytes were isolated and cultured from 
synovium of patients with RA, OA, and knee traumatic injury. 
The mass of tissue specimens obtained from each patient for cell 
culture were almost 30–50 g. Briefly, the collected synovial tissues 
were finely minced into pieces and transferred to a tissue culture 
flask in Dulbecco’s modified Eagle’s medium (DMEM) (Hyclone 
Laboratories, Losan, UT, USA) supplemented with 10% fetal 
bovine serum (FBS) (Hyclone Laboratories). Within 14  days, 
FLSs migrated out from the tissue explant and formed conflu-
ent monolayers. At approximately 80% confluency, FLSs were 
subsequently trypsinized, collected, re-suspended, and planted 
for expansion. FLSs of the three to five generation showed typical 
morphological characters under phase contrast microscope and 
the expression level of CD55 was over 95% using flow cytometry 
method. To examine the effect of Smo on cell migration and 
activation of RhoA and Rac1 of RA-FLSs, cells were incubated 
with Smo agonist (purmorphamine, 5 µmol/l) or Smo antagonist 
(KAAD-cyclopamine, 1 µmol/l) for 24 h. The control group was 
treated with vehicle (dimethyl sulfoxide in DMEM supplemented 
with 10% FBS).
rna isolation and real-time Pcr analysis
Total RNA was extracted using Trizol reagent (Invitrogen Life 
Technologies, Santa Clara, CA, USA). cDNAs were synthesized 
from the isolated total RNA using the Prime Script®RT Reagent 
Kit (Takara Biotechnology, Dalian, China) according to the 
manufacturer’s protocols. Quantification of the expression of 
human Smo and GAPDH mRNAs was determined using SYBR® 
Premix Ex TaqTM Kit (Takara Biotechnology) on an ABI-7500 
Thermal Cycler (Applied Biosystems Inc., Foster City, CA, USA) 
according to the manufacturer’s instructions. All experiments 
were examined in triplicate and positive (sample from liver 
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cancer cells containing Smo nucleotide sequence) and negative 
(sterile deionized water containing no template) controls were 
included. Relative levels were quantified using the comparative 
ΔCt method. The expression of mRNA in FLSs of RA and OA 
patients was given as fold change of mRNA abundance relative to 
that in FLSs of patients with knee trauma. Primers for amplifica-
tion were as follows (forward, reverse): Smo: forward: 5′-CCT 
GCT CAC CTG GTC ACT C-3′, reverse: 5′-CAC GGT ATC 
GGT AGT TCT TGT AG-3′, GAPDH: (5′-GGA TAT TGT TGC 
CAT CAT TdT dT-3′, 5′-AAT GAT GGC AAC AAT ATC CdT 
dT-3’).
Western Blot analysis
Total protein was extracted using a cell lysis buffer containing 
protease and phosphatase inhibitors (Cell Signaling Technology, 
Beverly, MA, USA). Protein lysates (30 µg protein) were loaded 
and separated by 12% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and then transferred to a poly-
vinylidene fluoride (PVDF) membrane. The membranes were 
blocked at room temperature for 2  h and probed overnight at 
4°C with primary antibodies. Primary antibodies included rabbit 
anti-Smo (1:2,000, Santa Cruz Biotechnology, Dallas, TX, USA), 
and the phosphorylation of myosin phosphatase targeting subu-
nit 1 (MYPT1, 1:500, Cell Signaling Technology, Beverly, MA, 
USA). Membranes were subsequently incubated with secondary 
antibodies conjugated with horseradish peroxidase at room tem-
perature for 1  h and the immobilized proteins were measured 
by the enhanced chemiluminescent (ECL) detection system. The 
band density was quantified by AlphaView software (San Jose, 
CA, USA).
cell Migration
Migration ability of FLSs was measured in a Transwell cell 
culture chamber apparatus with 8 µm pore membrane (Costar, 
New York, NY, USA). Briefly, FLSs were seed at a density of 
5  ×  104  cells/ml in six-well plates. Twelve hours later, FLSs 
were trypsinized, collected, and re-suspended with serum-free 
medium. The cell suspension (5 × 103 cells/ml) was loaded into 
the upper chamber of the Transwell insert. Medium containing 
10% FBS (600 µl) was added to the lower compartment as a che-
moattractant. After 8 h of incubation, the filters were removed 
and cells remaining on the upper surface of the membrane were 
removed with a cotton swab. The cells adhering beneath the 
membrane were fixed in 4% paraformaldehyde and stained with 
crystal violet for 30 min. Migration ability of FLSs was quanti-
fied by cell counts of five random fields at 100 magnifications in 
each membrane.
Pull-Down assay
To determine the activation of RhoA and Rac1 in FLSs of RA, 
OA, and patients of knee trauma, and the effect of Smo on 
RhoA and Rac1 activation in RA-FLSs, pull-down assays were 
performed according to the manufacturer’s protocol (RhoA 
activation assay kit and Rac1 activation assay kit, Millipore, MA, 
USA). Briefly, at 80% confluency, FLSs were lysed and the lysates 
were collected and stored at −80°C for the pull-down assay. 
Thirty microliters of the Rho or Rac1 Assay Reagent were added 
to 500 µl cell extract and the reaction mixtures were incubated 
for 45 min at 4°C with gentle agitation. After brief centrifuga-
tion (10  s, 14,000 ×  g, 4°C), the agarose beads were washed 
three times with 1× MLB, the supernatant was removed, and 
the agarose beads were re-suspended in 2× Laemmili-reducing 
sample buffer. Bound proteins were collected and examined by 
Western Blot analysis as previously described. GTP-RhoA or 
GTP-Rac1 was detected using anti-RhoA (3  µg/ml, Millipore, 
MA, USA) or anti-Rac1 antibodies (1  µg/ml, Millipore, MA, 
USA), respectively.
rna interfering
Three sequences of siRNA targeting human Smo (Smo-
homo-1542, Smo-homo-1292, Smo-homo-1732, Gene Pharma 
Co., Shanghai, China) were designed and synthesized. Smo-
homo-1542: 5′-GGA GUC AUG ACU CUG UUC UTT-3′; 
5′-AGA ACA GAG UCA UGA CUC CTT-3′; Smo-homo-1292: 
5′-CUG GCA CAC UUC CUU CAA ATT-3′; 5′-UUU GAA 
GGA AGU GUG CCA GTT-3′; Smo-homo-1732: 5′-GGG ACU 
AUG UGC UAU GUC ATT-3′; 5′-UGA CAU AGC ACA UAG 
UCC CTT-3′; GAPDH: 5′-GGA TAT TGT TGC CAT CAT TdT 
dT-3′; 5′′-AAT GAT GGC AAC AAT ATC CdT dT-3′; negative 
control: 5′-UUC UCC GAA CGU GUC ACG UTT-3′; 5′-ACG 
UGA CAC GUC GGA GAA TT-3′. At 40% confluency, RA-FLSs 
were transfected with siRNAs against Smo using the X-treme 
GENE siRNA transfection reagent (Roche, Mannheim, Germany) 
according to the manufacturer’s protocol. A glyceraldehyde-
3-phosphate dehydrogenase (GAPDH-siRNA) positive control, 
a negative control siRNA (NC-siRNA group), and mock trans-
fection (control group) were used for the studies. Cell viability 
after transfection was declined in some degree, but there is no 
statistical difference between experiment groups and control 
groups. The transfection efficiency was assessed by fluorescence 
microscopy 6 h after transfection with FITC-conjugated control 
siRNA. Transfection efficiency was over 90%. Gene silencing 
efficiency was determined 48 h posttransfection by Western Blot 
analysis.
statistical analysis
SPSS statistical software, version 17.0 (Chicago, IL, USA), 
was used for all statistical analyses. Values are presented as 
means ± SD. Statistical differences among groups were tested by 
one-way analysis of variance (ANOVA) or the Kruskal–Wallis 
test. Statistical significance was set at P < 0.05.
resUlTs
sMO Was highly expressed in cultured 
Flss from ra Patients
Expression of Smo mRNA was detected in FLSs from RA, OA, 
and patients of knee trauma utilizing real-time PCR. Although 
Smo mRNA was expressed in FLSs isolated from RA, OA 
patients, and patient with traumatic injury, its levels were sig-
nificantly greater in RA-FLSs than on FLSs from patients with 
knee trauma (Figure  1A). Western Blot analysis demonstrated 
that the expression of Smo protein in FLSs from RA patients 
FigUre 1 | smo was highly expressed in cultured fibroblast-like 
synoviocytes (Flss) from rheumatoid arthritis (ra) patients. RA-FLSs, 
OA-FLSs, and FLSs from patients with knee traumatic injury were isolated 
and cultured. The expression of Smo mRNA was detected by real-time PCR. 
Relative quantification of gene expression was performed by the 2−∆∆Ct  
method (a). The expression of Smo protein was examined by Western Blot 
analysis (B). The results represent the mean ± SD of three independent 
experiments. *P < 0.05 versus control group.
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was also higher compared to FLSs from patients with traumatic 
injury (Figure 1B). Interestingly, both Smo mRNA and protein 
were expressed in FLSs of OA (OA-FLSs), but the expression was 
significantly lower compared to that of RA-FLSs.
Flss from ra Patients showed Property 
of Migration and activation of rho gTPase 
signaling
In order to examine the property of migration of FLSs from 
patients of RA, OA, and knee trauma, we conducted Transwell 
assay and observed that the numbers of migrated cells were sig-
nificantly higher in RA-FLSs (133.00 × 104 ± 4.73 × 104) than that 
in OA-FLSs (81.33 × 104 ± 1.45 × 104) and FLSs from patients 
with traumatic injury (45.67 ×  104 ±  4.48 ×  104) (P <  0.05) 
(Figure 2C). To further investigate whether the higher levels of 
migration rates of RA-FLSs were associated with activation of 
Rho GTPases, we determined the activation of RhoA and Rac1 
using pull-down assays. The results revealed that the activities 
of RhoA and Rac1 were significantly increased in RA-FLSs, 
compared to that in OA-FLSs and FLSs from patients of trauma 
(Figures 2A,B).
smo agonist and antagonist regulates 
ra-Flss Migration and rho gTPase 
signaling
To investigate the effect of Smo on RA-FLSs migration, FLSs cells 
were treated in the presence of Smo agonist (purmorphamine, 
5  µmol/l) or Smo antagonist (KAAD-cyclopamine, 1  µmol/l). 
As shown in Figure 3A, expression of Smo protein was signifi-
cantly decreased after incubation with KAAD-cyclopamine and 
increased after treatment with purmorphamine. Furthermore, 
we found that purmorphamine effectively increased the num-
bers of migrated cells (155.70 ×  104 ±  3.84 ×  104), compared 
to controls (122.70  ×  104 ±  2.73  ×  104) (P <  0.05). We also 
observed that the migration of RA-FLSs significantly decreased 
by KAAD-cyclopamine, with decreased numbers of migrated 
cells 75.33 ×  104 ±  1.45 ×  104 (P <  0.05) compared to control 
incubation (Figure 3B).
To elucidate the effects of purmorphamine and KAAD-
cyclopamine on Rho GTPase signaling, the activities of RhoA and 
Rac1 were examined in the current study. The results revealed 
that incubation of purmorphamine significantly increased the 
activities of RhoA and Rac1 in RA-FLSs, compared to the controls 
(Figures  3C,D). Accordingly, the activities of RhoA and Rac1 
were significantly inhibited in the presence of Smo antagonist 
(Figures 3C,D). To further investigate the activation of RhoA/
Rho-associated kinase (ROCK) signaling by Smo modulation, 
the effector of RhoA/ROCK, the levels of phosphorylation of 
MYPT1 were determined by Western Blot analysis in this study. 
Quantification demonstrated that phospho-MYPT1 was largely 
induced by purmorphamine in RA-FLSs. By contrast, inhibition 
of Smo significantly decreased the phosphorylation of MYPT1 
(Figure 3E).
Knockdown of sMO Mediated by sirna 
Decreased ra-Flss Migration and 
gTPase signaling
Based on the above findings, we used RNA interference as an 
alternative approach to further determine the role of Smo in 
migration of RA-FLSs and to explore the underlying molecular 
mechanisms. RA-FLSs were transfected with a NC-siRNA and 
siRNAs directed against Smo (Smo-siRNA). The efficiency of 
the transfection was monitored by Western Blot analysis after 
48  h of incubation with siRNAs. The results revealed that the 
expression of Smo is predominantly inhibited in Smo-targeted 
siRNA-transfected cells versus NC-siRNA-transfected cells 
(Figure  4A). Cell migration was measured using Transwell 
assay and activation of Rho GTPase signaling was assessed using 
pull-down assay. The results of migration assay showed that sup-
pression of Smo decreased the migration of RA-FLSs, with the 
numbers of migrated cells 40.33 × 104 ± 3.28 × 104, compared to 
that of the NC-siRNA group (99.00 × 104 ± 6.81 × 104, Figure 4E, 
P < 0.05). Thus, suppression of Smo significantly inhibited the 
activation of RhoA and Rac1 in RA-FLSs, compared to that of 
NC-siRNA group (Figures 4B,C, P <  0.05). The Western Blot 
analysis showed that the levels of MYPT1 phosphorylation 
were also significantly inhibited after Smo-siRNA transfection 
(Figure 4D).
DiscUssiOn
FLSs in the synovial intimal lining not only act as passive 
responders in the progression of RA, but also acquire an 
aggressive phenotype and increase invasiveness into the extra-
cellular matrix, contributing to pannus formation and cartilage 
destruction. In the current study, we observed the excessive 
migration in RA-FLSs compared to OA-FLSs and FLSs from 
FigUre 2 | Fibroblast-like synoviocytes (Flss) from rheumatoid arthritis (ra) patients showed property of migration and activation of rho gTPase 
signaling. RA-FLSs, OA-FLSs, and FLSs from patients with knee traumatic injury were isolated and cultured. The activation of RhoA and Rac1 was detected by 
pull-down assays (a,B). Cell migration was evaluated using Transwell assays and the numbers of migrated cells were calculated (×104 cells/ml) [(c), d] and 
representative images of migrated cells in RA-FLSs [(c), a], OA-FLSs [(c), b], and FLSs from patients of traumatic injury [(c), c] were displayed (100 magnifications). 
The results represent the Mean ± SD of three independent experiments. *P < 0.05 versus control group.
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patients with knee traumatic injury. Combining with our 
recent report that Shh signaling is aberrantly activated in RA 
patients and inhibition of the key component of Shh signal-
ing, Smo, decreases proliferation of RA-FLSs, we propose that 
Smo could be a potential target for the FLSs-directed therapies 
for RA.
Small-molecule inhibitors targeting Smo have been syn-
thesized for the treatment of cancers. Vismodegib, one of the 
small-molecular inhibitors, has been approved for patients with 
advanced BCC. It is reported that the small-molecule inhibi-
tors against Smo exert its antitumor activities by inhibiting cell 
growth and invasion and inducing apoptosis in cancer cells (20, 
FigUre 3 | smo agonist and antagonist regulated rheumatoid arthritis (ra)-fibroblast-like synoviocytes (Flss) migration and rhogTPase signaling. 
RA-FLSs were cultured for 24 h before incubation with Smo agonist (purmorphamine, 5 µmol/l) or Smo antagonist (KAAD-cyclopamine, 1 µmol/l) for 24 h. The 
effects of purmorphamine and KAAD-cyclopamine on the expression of Smo were measured by Western Blot analysis, and Smo expression was evaluated and 
normalized to GAPDH (a). Cell migration was evaluated using Transwell assays and the numbers of migrated cells were calculated (×104 cells/ml) [(B), d]. 
Representative images of RA-FLSs migration after treatments with purmorphamine [(B), a], KAAD-cyclopamine [(B), b], or vehicle [(B), c] were displayed (100 
magnifications). The activation of RhoA and Rac1 was detected by pull-down assays (c,D). Expression of MYPT1 was detected by Western Blot analysis and the 
levels of phospho-MYPT1 were normalized to expression of total MYPT1 (e). The results are the mean ± SD of three independent experiments. *P < 0.05 versus 
control group. pur, purmorphamine; K-cyc, KAAD-cyclopamine; MYPT1, myosin phosphatase targeting subunit 1.
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21). Previous in vitro study showed that vismodegib slows down 
migration by downregulating E-Cadherin expression in lung 
squamous cell carcinomas (22). In the current study, we showed 
that blockage of Smo with antagonist KAAD-cyclopamine or 
small interfering RNA suppressed migration of RA-FLSs, 
whereas upregulation of Smo promotes migration of RA-FLSs, 
suggesting that Smo may play a critical role in the regulation 
of RA-FLSs migration. However, it remains unclear how Smo 
promotes RA-FLSs migration and its role in the pathogenesis 
of RA.
Classically, activated Smo functions through activation of 
transcription factors belonging to the Gli family and expression 
of downstream target genes, involving proliferation (cyclin D 
and cyclin E), survival (BCL-2), metastasis (Snail), and stem cell 
activation (NANOG and SOX2) (23). However, as a canonical G 
protein-coupled receptor, Smo is reported to signal through a G 
protein (24) and involves in a non-canonical signaling of Shh. 
The studies performed by Polizio et al. revealed that Shh-induced 
fibroblast migration depends on the coupling of Smo to Gi pro-
teins and is mediated by the stimulation of GTPases RhoA and 
Rac1 (5, 25). The results reported previously also showed that Shh 
stimulates tubulogenesis of endothelial cells in a non-canonical 
fashion, which is mediated by Smo, Gi proteins and Rho GTPases 
(11). In the present study, enhanced migration and Rho GTPase 
signaling activation in RA-FLSs are observed. Therefore, it is likely 
that Smo functions to induce RA-FLSs migration via activation of 
Rho GTPase signaling.
The Rho GTPases are known to serve as molecular switches 
and play central roles in directional migration by regulating 
organization of actin cytoskeleton and controlling cellular motil-
ity and polarity (26). Four members, including Rac1, Rac2, RhoA, 
and Cdc42 are best characterized in the Rho GTPases family and 
RhoA and Rac1 are identified to play major roles in the regulation 
of RA-FLSs migration. Using pull-down assays, we further vali-
dated the effect of Smo modulation on Rho GTPases activation in 
RA-FLSs and demonstrated that RA-FLSs are directly responsive 
FigUre 4 | Knockdown of smo mediated by sirna decreased rheumatoid arthritis (ra)-fibroblast-like synoviocytes (Flss) migration and 
rhogTPase signaling. RA-FLSs were cultured and transfected with small interfering RNAs directed against Smo (Smo-siRNA) or with a negative control siRNA 
(NC-siRNA) for 48 h. Silencing efficiency was measured by Western Blot analysis (a). The activation of RhoA and Rac1 was detected by pull-down assays (B,c). 
Expression of MYPT1 was detected by Western Blot analysis and the levels of phospho-MYPT1 were normalized to expression of total MYPT1 (D). Cell migration 
was evaluated using Transwell assays and the numbers of migrated cells were calculated (×104 cells/ml) (e). Representative images of RA-FLSs migration after 
being transfected small interfering RNAs directed against Smo (Smo-siRNA) [(e), a], a NC-siRNA [(e), b], or vehicle [(e), c] were displayed (100 magnifications). The 
results are the mean ± SD of three independent experiments. *P < 0.05 versus control group. MYPT1, myosin phosphatase targeting subunit 1.
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FigUre 5 | non-canonical signaling pathway of shh. By coupling of G 
protein-coupled receptors, Smo modulates the activation of RhoA/ROCK 
(MYPT1) signaling through increasing/decreasing MLCP level to enhance/
weaken traction force, which results in promoting/reducing rheumatoid arthritis 
(RA)-fibroblast-like synoviocytes (FLSs) migration. On the other side, Rac1 
induces actin polymerization to promote RA-FLSs migration through its 
downstream protein such as WAVE/ARP2/3 complex. It is likely that Smo serves 
as a principal mediator of cytoskeletal tension in the process of cell migration.
8
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modulates the activation of RhoA/ROCK (MYPT1) signaling 
through increasing/decreasing MLCP level to enhance/weaken 
traction force, which resulting in promoting/reducing RA-FLSs 
migration. On the other side, Rac1 induces actin polymeriza-
tion to promoting RA-FLSs migration through its downstream 
protein such as WAVE/ARP2/3 complex (Figure 5).
Therefore, Smo seems to be a principal mediator of cytoskel-
etal tension in the process of cell migration. The results indicate 
that Smo is not only involved in RA-FLSs proliferation but also 
plays an important role in the progression of RA-FLSs migration 
through the activation of Rho GTPase signaling. However, the 
changes of actin cytoskeleton of RA-FLSs responding to Smo 
remain to be further investigated.
cOnclUsiOn
In the current study, we have identified a new effect of Smo on 
RA-FLSs migration and elucidated underlying molecular mecha-
nisms by which the Shh pathway is linked to cell migration. These 
findings may provide a potential therapeutic target to suppress 
the aggressive phenotype of RA-FLSs and control pathological 
synovial invasion in RA.
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